The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
The HBV Drug Entecavir — Effects on HIV-1 Replication and Resistance
Open accessAbstract
Sum m a r yEntecavir, a drug approved by the Food and Drug Administration for the treatment of chronic hepatitis B virus (HBV) infection, is not believed to inhibit replication of human immunodeficiency virus type 1 (HIV-1) at clinically relevant doses.We observed that entecavir led to a consistent 1-log 10 decrease in HIV-1 RNA in three persons with HIV-1 and HBV coinfection, and we obtained supportive in vitro evidence that entecavir is a potent partial inhibitor of HIV-1 replication.Detailed analysis showed that in one of these patients, entecavir monotherapy led to an accumulation of HIV-1 variants with the lamivudine-resistant mutation, M184V.In vitro experiments showed that M184V confers resistance to entecavir.Until more is known about HIV-1-resistance patterns and their selection by entecavir, caution is needed with the use of entecavir in persons with HIV-1 and HBV coinfection who are not receiving fully suppressive antiretroviral regimens. Entecavir, an analogue of 2′-deoxyguanosine, is converted intracellularly to an active 5′-triphosphate form that inhibits hepatitis B virus (HBV) polymerase.[1][2][3] Entecavir is approved by the Food and Drug Administration for the treatment of chronic hepatitis B infection.A previous study 1 indicated that it has no clinically relevant activity against human immunodeficiency virus type 1 (HIV-1), and the package insert states that the concentration needed to inhibit replication by 50% (EC 50 ) for HIV-1 is greater than 1 μM, which is higher than concentrations achieved in vivo with dosages used to treat chronic hepatitis B. Because of this selective activity against HBV, 4-7 several treatment guidelines, including the U.S. Public Health Service guidelines, recommend entecavir for hepatitis B treatment in HIV-1-infected persons who do not meet criteria for HIV-1 treatment.[8][9][10][11] Here, we report that entecavir has clinically relevant activity against HIV-1 and can select HIV-1 variants resistant to the widely used antiretroviral drugs lamivudine and emtricitabine. C a se R ep or t s Patient 1Patient 1 is a 31-year-old white man with HIV-1 and HBV coinfection who tested seropositive for HIV-1 in 1990.In 2000, he received zidovudine, lamivudine, and nevirapine for the treatment of HIV-1.He took these drugs intermittently for less than 1 year.In February 2002, his CD4+ T-cell count was 596 cells per cubic millimeter,
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
(2002) · PsycEXTRA Dataset · doi:10.1037/e548512006-001 · Cited by 1,708
Zack, J. A., Arrigo, S. J., Weitsman, S. R., Go, A. S., Haislip, A., & Chen, I. S. Y. (1990) · Cell · doi:10.1016/0092-8674(90)90802-l · Cited by 1,517
Weislow, O. S., Kiser, R., Fine, D. L., Bader, J., Shoemaker, R. H., & Boyd, M. R. (1989) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/81.8.577 · Cited by 685
A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1
Petropoulos, C. J., Parkin, N. T., Limoli, K. L., Lie, Y., Wrin, T., Huang, W., Tian, H., Smith, D., Winslow, G. A., Capon, D. J., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.920-928.2000 · Cited by 646
Tisdale, M., Kemp, S. D., Parry, N. R., & Larder, B. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5653 · Cited by 603
Doong, S. L., Tsai, C. H., Schinazi, R. F., Liotta, D. C., & Cheng, Y. C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8495 · Cited by 516
Schuurman, R., Nijhuis, M., van Leeuwen, R., Schipper, P., de Jong, D., Collis, P., Danner, S. A., Mulder, J., Loveday, C., Christopherson, C., et al. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1411 · Cited by 503
Bailey, J. R., Sedaghat, A. R., Kieffer, T., Brennan, T., Lee, P. K., Wind-Rotolo, M., Haggerty, C. M., Kamireddi, A. R., Liu, Y., Lee, J., et al. (2006) · Journal of Virology · doi:10.1128/jvi.00591-06 · Cited by 417
Self-citationBack, N. K., Nijhuis, M., Keulen, W., Boucher, C. A., Oude Essink, B. O., van Kuilenburg, A. B., van Gennip, A. H., & Berkhout, B. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00777.x · Cited by 406
Cited by
Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Detection and quantification of rare mutations with massively parallel sequencing
Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K. W., & Vogelstein, B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105422108 · Cited by 1,144
Dienstag, J. L. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801644 · Cited by 961
Metadata
- Authors
- McMahon, M. A., Jilek, B. L., Brennan, T. P., Shen, L., Zhou, Y., Wind-Rotolo, M., Xing, S., Bhat, S., Hale, B., Hegarty, R., Chong, C. R., Liu, J. O., Siliciano, R. F., & Thio, C. L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-21
- Volume
- 356
- Issue
- 25
- Pages
- 2614-2621
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1981526509
- Cited by
- 292
- References
- 21
- FWCI
- 27.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The HBV Drug Entecavir — Effects on HIV-1 Replication and Resistance. https://app.cochat.ai/papers/10.1056/nejmoa067710
- The paper
- McMahon, M. A., Jilek, B. L., Brennan, T. P., Shen, L., Zhou, Y., Wind-Rotolo, M., Xing, S., Bhat, S., Hale, B., Hegarty, R., Chong, C. R., Liu, J. O., Siliciano, R. F., & Thio, C. L. (2007). The HBV Drug Entecavir — Effects on HIV-1 Replication and Resistance. New England Journal of Medicine. https://doi.org/10.1056/nejmoa067710
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.